|
|
New Target Identification
Cambridge Biotechnology uses a combination of public data along with in-house data derived
from its proprietary gene-expression based target identification platform to discover
tractable new targets for both small-molecule and biopharmaceutical drug discovery.
CBT has developed a proprietary target selection process which ensures that the best
targets are taken forward to develop therapies for each particular disease indication
in the most appropriate way.
|
|
